The ratio of cannabidiol (CBD) to tetrahydrocannabinol (THC) in medicinal cannabis has shown to play a crucial role in improving the physical and functional wellbeing of brain cancer patients, according to newly published findings in a trial funded by BioCeuticals, the practitioner-only arm of Blackmores. Findings from a new study examining human and canine brain cancer cells suggest that cannabidiol could be a useful therapy for a difficult-to-treat brain cancer
Ratio matters: CBD and THC ratio plays key role improving quality of life in brain cancer patients – BioCeuticals-funded trial
The ratio of cannabidiol (CBD) to tetrahydrocannabinol (THC) in medicinal cannabis has shown to play a crucial role in improving the physical and functional wellbeing of brain cancer patients, according to newly published findings in a trial funded by BioCeuticals, the practitioner-only arm of Blackmores.
The 12-week double-blind RCT was conducted on 88 patients suffering from high-grade glioma – an aggressive brain cancer with a survival rate of six to 18 months.
Results from MRI scan of 53 participants also showed that 11 per cent of them reported a reduction in disease, 34 per cent were in stable conditions, 16 per cent had slight enhancement, and 10 per cent reported worsening of their condition.
Writing in Frontiers in Oncology, the researchers highlighted that a CBD to THC ratio of 1:1 led to more improvements in physical, functional capacities, as well as better sleep quality in these patients, as compared to the use of CBD to THC at the ratio of 1:4.
On the other hand, there was no difference between the two groups in terms of MRI tumour burden/control.
In other words, both ratios exerted similar effects when it comes to affecting the tumour size.
This is also said to be the first study that looked that medicinal cannabis use beyond pain relief and reduction of symptoms.
“Most of the other studies that are done in cancer for medicinal cannabis is actually for symptomatology, which means they are looking at how medicinal cannabis eases pain, nausea and vomiting.
“For this particular study, it was actually trying to look at the quality of life and the patients’ physical functionality, their ability to do everyday things such as walking, the moving of arms and legs, and being able to speak in a sentence.
“It also looked at how medicinal cannabis could enhance the current treatment that these particular patients are undergoing,” lead researcher Dr Janet Schloss told NutraIngredients-Asia.
CBD Shows Promise for Fighting Aggressive Brain Cancer
Newswise — Bethesda, MD – Findings from a new study examining human and canine brain cancer cells suggest that cannabidiol could be a useful therapy for a difficult-to-treat brain cancer. Cannabidiol, or CBD, is a non-psychoactive chemical compound derived from marijuana.
The study looked at glioblastoma, an often-deadly form of brain cancer that grows and spreads very quickly. Even with major advancements in treatment, survival rates for this cancer have not improved significantly.
“Further research and treatment options are urgently needed for patients afflicted by brain cancer,” said Chase Gross, a student in the Doctor of Veterinary Medicine/Master of Science program at Colorado State University. “Our work shows that CBD has the potential to provide an effective, synergistic glioblastoma therapy option and that it should continue to be vigorously studied.”
Mr. Gross was scheduled to present this research at the American Society for Pharmacology and Experimental Therapeutics annual meeting in San Diego this month. Though the meeting, to be held in conjunction with the 2020 Experimental Biology conference, was canceled in response to the COVID-19 outbreak, the research team’s abstract was published in this month’s issue of The FASEB Journal.
Mr. Gross and colleagues examined human and canine glioblastoma cells because the cancer shows striking similarities between the two species. They tested the effects of CBD isolate, which contains 100 percent CBD, and CBD extract, which contains small amounts of other natural occurring compounds such as cannabigerol and tetrahydrocannabinol, or THC.
“Our experiments showed that CBD slows cancer cell growth and is toxic to both canine and human glioblastoma cell lines,” said Mr. Gross. “Importantly, the differences in anti-cancer affects between CBD isolate and extract appear to be negligible.”
The new work revealed that the toxic effects of CBD are mediated through the cell’s natural pathway for apoptosis, a form of programmed cell death. The researchers also observed that CBD-induced cell death was characterized by large, swollen intracellular vesicles before the membrane begins to bulge and breakdown. This was true for all the cell lines studied.
The researchers believe that CBD’s anti-cancer actions target mitochondria—the cell’s energy producing structures—by causing the mitochondria to dysfunction and release harmful reactive oxygen species. Their experiments showed that cells treated with CBD exhibited significant decreases in mitochondrial activity.
“CBD has been zealously studied in cells for its anticancer properties over the last decade,” said Mr. Gross. “Our study helps complete the in vitro puzzle, allowing us to move forward in studying CBD’s effects on glioblastoma in a clinical setting using live animal models. This could lead to new treatments that would help both people and dogs that have this very serious cancer.”
Next, the researchers plan to transition from cell cultures to animal models to test CBD’s effects on glioblastoma. If the animal studies go well, the work could progress to clinical trials on dogs that are being treated for naturally occurring glioblastoma at the Colorado State University Veterinary Teaching Hospital.
Contact the media team for more information.
About Experimental Biology 2020
Experimental Biology is an annual meeting that attracts more than 12,000 scientists and exhibitors from five host societies and more than two dozen guest societies. With a mission to share the newest scientific concepts and research findings shaping clinical advances, the meeting offers an unparalleled opportunity for exchange among scientists from across the U.S. and the world who represent dozens of scientific areas, from laboratory to translational to clinical research. www.experimentalbiology.org #expbio
About the American Society for Pharmacology and Experimental Therapeutics (ASPET)